Michael C Mithoefer

Biographic Data

ID5455415
NAMEMichael C Mithoefer
GIVEN NAMESMichael C
FAMILY NAMEMithoefer
SIGNATUREMITHOEFER M C
AFFILIATIONSMedical University of South Carolina
ORCID0000-0002-4267-6135
VERIFIEDYes
TOTAL WORKS8
TOTAL CITATIONS1
WORKS AS AUTHOR8
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2011
LATEST PUBLICATION YEAR2023
H-INDEX1

  • Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder

    Open AccessS Parker Singleton, Julie B Wang et al.ARTICLEFrontiers in Psychiatry2023

    https://clinicaltrials.gov/ct2/show/NCT02102802, identifier NCT02102802

  • Group psychedelic therapy

    Open AccessElliot Marseille, Christopher S Stauffer et al.ARTICLEFrontiers in Psychiatry2023

    Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies. By enhancing the number of patients served per clinician, group therapy could also ameliorate the anticipated shortage of appropriately trained clinicians, thereby accelerating access to these promising new therapies

  • MDMA-assisted therapy for severe PTSD

    Open AccessJennifer M Mitchell, Michael P Bogenschutz et al.ARTICLENature Medicine2021

    Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities suc…

  • Relational and Growth Outcomes Following Couples Therapy With MDMA for PTSD

    Open AccessA C Wagner, Rachel E Liebman et al.ARTICLEFrontiers in Psychiatry2021

    Healing from trauma occurs in a relational context, and the impacts of traumatic experiences that result in post-traumatic stress disorder (PTSD) go beyond the diagnosis itself. To fully understand a treatment for PTSD, understanding its impact on interpersonal, relational, and growth outcomes yields a more fulsome picture of the effects of the treatment. The current paper examines these secondary outcomes of a pilot trial of Cognitive Behavioral…

  • Scaling Up

    Open AccessJulie B Wang, Jessica Lin et al.ARTICLEJournal of Humanistic Psychology2021Cited by: 1References: 29

    Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized therapy across 14 North American sites. Method: Cotherap…

  • Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA)

    A C Wagner, Michael C Mithoefer et al.ARTICLEJournal of Psychoactive Drugs2019

    Treatments for posttraumatic stress disorder (PTSD) have evolved significantly in the past 35 years. From what was historically viewed as a pervasive, intractable condition have emerged multiple evidence-based intervention options. These treatments, predominantly cognitive behavioral in orientation, provide significant symptom improvement in 50-60% of recipients. The treatment of PTSD with MDMA-assisted psychotherapy using a supportive, non-direc…

  • The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder

    Open AccessMichael C Mithoefer, Mark T Wagner et al.ARTICLEJournal of Psychopharmacology2011

    Case reports indicate that psychiatrists administered ±3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy before recreational use of MDMA as ‘Ecstasy’ resulted in its criminalization in 1985. Over two decades later, this study is the first completed clinical trial evaluating MDMA as a therapeutic adjunct. Twenty patients with chronic posttraumatic stress disorder, refractory to both psychotherapy and psychopharmacology, were …

  • Long-Term Abstinence Following Holotropic Breathwork as Adjunctive Treatment of Substance Use Disorders and Related Psychiatric Comorbidity

    Open AccessTimothy D Brewerton, James Eyerman et al.ARTICLEInternational Journal of Mental…2011